Conditions: Schizophrenic Disorders
Keywords: schizophrenia SWNK
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 798
Healthy volunteers: no

Brief summary:
The trial is designed to assess the long term subjective well-being in schizophrenic outpatients treated with quetiapine XR (extended release) or oral risperidone at flexible dose in a naturalistic setting over a period of one year. Secondary outcome measures have been selected for helping in the differentiation of the compared atypical antipsychotics. The primary objective of this study is to demonstrate the non-inferiority of quetiapine XR to risperidone assessed at month 6 in terms of responder rate using the self-report instrument SWN-K

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Quetiapine XR intervention 2: Risperidone
Intervention descriptions: intervention 1: Oral, once daily, tablets of 400 mg to 800 mg intervention 2: Oral, once daily, tablets of 2 mg to 6 mg

Protocol document: